Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Maxime Battistella, Alejandro A. Gru, Hélène Moins-Teisserenc, Martine Bagot, Youn-H H. Kim, Larisa J Geskin, Pablo L Ortiz-Romero, Ellen Kim, Neha Mehta-Shah, Olivier Dereure, Saskia Oro, Lubomir Sokol, Marie Beylot-Barry, Stéphane Dalle, Eric D. Jacobsen, Frederick Lansigan, Caroline Ram-Wolff, Michael S. Khodadoust, Pier Luigi Zinzani, Julien Viotti, David Magrez, Agnes Boyer Chammard, Constance Vagne, Flavien Carraguel, Laura Assante Miranda, Valentine Peri, Sivan Bokobza, Marie-Laure Thibult, Cécile Bonnafous, Florent Carrette, Pierluigi Porcu
Institutions: Hôpital Saint-Louis, Columbia University Irving Medical Center, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Ecotaxie, Microenvironnement et développement lymphocytaire, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Stanford Medicine, Stanford University, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, University of Pennsylvania, Washington University in St. Louis, Centre Hospitalier Universitaire de Montpellier, Université Montpellier 1, Hôpitaux Universitaires Henri-Mondor, Moffitt Cancer Center, Centre Hospitalier Universitaire de Bordeaux, Hospices Civils de Lyon, Dana-Farber Cancer Institute, Dartmouth–Hitchcock Medical Center, University of Bologna, Innate Pharma (France), Thomas Jefferson University, Sidney Kimmel Cancer Center
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405041941